Concepedia

Author

Josh Bliesath

Plex Pharmaceuticals (United States)

Also Known As

J. Bliesath, Josh Bliesath

30

Publications

2.2K

Citations

6

H-Index

23

Concepts

All Affiliations

Plex Pharmaceuticals (United States)
JB

About

Josh Bliesath is an author at Plex Pharmaceuticals (United States) specializing in medicine, molecular biology, and drug discovery.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

769

2

Molecular Biology

3

3

769

3

Engineering

2

2

183

4

Cell Biology

2

2

613

5

Biomolecular Engineering

1

1

156

Josh Bliesath

×

6

Publications

2.2K

Citations

6

H-Index

YearCitations

Targeting RNA Polymerase I with an Oral Small Molecule CX-5461 Inhibits Ribosomal RNA Synthesis and Solid Tumor Growth

Denis Drygin, Amy Lin, Josh Bliesath,

Cancer Research

2010

610

Anticancer Activity of CX-3543: A Direct Inhibitor of rRNA Biogenesis

Denis Drygin, Adam Siddiqui-Jain, Sean O’Brien,

Cancer Research

2009

586

CX-4945, an Orally Bioavailable Selective Inhibitor of Protein Kinase CK2, Inhibits Prosurvival and Angiogenic Signaling and Exhibits Antitumor Efficacy

Adam Siddiqui-Jain, Denis Drygin, Nicole Streiner,

Cancer Research

2010

501

Discovery and SAR of 5-(3-Chlorophenylamino)benzo[<i>c</i>][2,6]naphthyridine-8-carboxylic Acid (CX-4945), the First Clinical Stage Inhibitor of Protein Kinase CK2 for the Treatment of Cancer

Fabrice Pierre, Peter Chua, Sean O’Brien,

Journal of Medicinal Chemistry

2010

295

Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics

Mustapha Haddach, Michael K. Schwaebe, Jerome Michaux,

ACS Medicinal Chemistry Letters

2012

156

A more efficient RNAi inducible system for tight regulation of gene expression in mammalian cells and xenograft animals

Jing Zhang, Cuiying Wang, Ke Ning,

RNA

2007

27

Page 1